Furthermore, we seek to validate the neuroprotective and anti-inflammatory potential of SIRT 2 inhibition with the use of cell culture models of dopaminergic neurodegeneration and microglial activation, respectively, highlighting this HDAC as a potential therapeutic target for the treatment of PD. Here, HDAC9 is linked to Parkinson disease.